


Science of 2020 Biotech IPOs – Large Molecule drughunter.com

Large Molecule R&D Co's Newly Listed on US Exchanges via IPO in 2020 (page 1/3)

Company	SYMB	Lead	Lead Mechanism	Stage	Other Programs	Cap* (M)
CureVac N.V.	CVAC	CVnCoV	COVID-19 mRNA vaccine	Ph. III	rabies mRNA vaccine	\$9,379
I-Mab	IMAB	TJM2 or plonmarlimab	GM-CSF neutralizing mAb for autoimmune diseases	Ph. II	CD47 mAb	\$5,957
AbCellera Biologics	ABCL	bamlanivimab	SARS-CoV2 spike protein mAb	EUA/Ph. III	SARS-CoV2 variant mAb	\$4,587
ALX Oncology	ALXO	ALX148	CD47 blocking fusion protein for cancer	Ph. II	SIRP α /TLR agonist ADC	\$2,193
Pandion Therapeutics**	PAND	PT101	IL-2R activating IL-2 mut./Fc-fusion for inflamm. diseases	Ph. I	**acquired by Merck	\$1,850
ADC Therapeutics SA	ADCT	loncastuximab tesirine-lpyl (Zynlonta)	CD19-targeting ADC (PBD) for DLBCL	Mktd.	CD25-targeting ADC, Ph. 2	\$1,750
Applied Molecular Transport	AMTI	AMT-101	oral GI-selective IL-10-cholix fusion protein for inflamm.	Ph. II	IL-22 fusion biologic for GI barrier repair (AMT-126, Ph. 1)	\$1,441
BioAtla	BCAB	BA3011	AXL-targeting conditionally-active biologic (CAB) ADC for AXL+ cancer	Ph. II	ROR2 tyrosine kinase ADC (Ph. 2), CTLA-4 CAB-antibody	\$1,316
Cullinan Management	CGEM	CLN-049	FLT3/CD3 bispecific mAb for AML	IND-enab.	MICA/B mAb (IND-enab.)	\$1,173

*as of Jul. 19, 2021




CVnCoV




TJM2




bamlanivimab



ALX148




loncastuximab tesirine



AMT-101



BA3011



CLN-049


Science of 2020 Biotech IPOs – Large Molecule [drughunter.com](https://www.drughunter.com)

Large Molecule R&D Co's Newly Listed on US Exchanges via IPO in 2020 (page 2/3)


Company	SYMB	Lead	Lead Mechanism	Stage	Other Programs	Cap (M)
Vaxcyte	PCVX	VAX-24	polysaccharide-antigen conjugated to eCRM protein carrier (vaccine)	preclin.	--	\$1,105
Silverback Therapeutics	SBTX	SBT6050	HER2-targeted, TLR8 agonist ADC for cancer	Ph. I	Nectin4 ADC for cancer	\$1,068
Inhibrx	INBX	INBRX109	DR5 agonist antibody for immunotherapy	Ph. II	OX40 agonist, hexavalent sdAb (INRX106, Ph. 1)	\$995
Dyne Therapeutics	DYN	DM1 program	antibody-oligonucleotide conjugate targeting DMPK RNA for myotonic dystrophy	preclin.	exon 51, 53, 45, 44 for DMD	\$973
Shattuck Labs	STTK	SL-172154	SIRP α - and CD40L-targeting fusion protein for cancer	Ph. I	PD-1 and OX40L (SL-279252, Ph. 1)	\$964
Keros Therapeutics	KROS	KER-050	TGF β ligand-trap protein for myelodysplastic syndrome (MDS)	Ph. II	Activin A, B targeting fusion of ActRIIB to Fc (KER-012, preclin.)	\$931
Annexon Biosciences	ANNX	ANX005	C1q-targeting mAb for complement pathway inh. for antibody-med. autoimmune/neurodegen. Diseases	Ph. II/III	C1q-targeting mAb (ANX007 Ph. 2) for geographic atrophy	\$880
Avidity Biosciences	RNA	AOC 1001	antibody-oligonucleotide conjugate (AOC) targeting DMPK RNA for myotonic dystrophy	IND-enabling	DUX4 AOC for FSHD (discovery)	\$856




VAX-24




SBT6050




INBRX109



DM1 AOC




SL-172154



KER-050



ANX005



AOC 1001


Science of 2020 Biotech IPOs – Large Molecule [drughunter.com](https://www.drughunter.com)

Large Molecule R&D Co's Newly Listed on US Exchanges via IPO in 2020 (page 3/3)


Company	SYMB	Lead	Lead Mechanism	Stage	Other Programs	Cap (M)
Aligos Therapeutics	ALGS	ALG-010133	oligonucleotide polymer hep. B S-antigen transport inhibitor to enhance immunity vs. chronic hep. B.	Ph. I	HbSag ASO (ALG-020572, preclin.)	\$659
Greenwich LifeSciences	GLSI	GP2 peptide	HER2/neu-derived GP2 peptide to elicit immune response for breast cancer	Ph. III	--	\$530
Inozyme Pharma	INZY	INZ-701	ENPP1 enzyme derivative to replace non-functional enz.	Ph. I/2	INZ-701 for calciphylaxis (IND-enab.)	\$424
Codiak BioSciences	CDAK	exoIL-12	exosomal IL-12 to stimulate T-cell and NK cell activity in T-cell lymphoma	Ph. I	small mol. STING agonist exosomes for solid tumors (Ph. 1)	\$352
Fusion Pharmaceuticals	FUSN	FPI-1434	IGF-1R-targeting mAb linked to radioactive [225Ac] payload for tumors	Ph. I	FGFR3-targeting mAb (FPI-1966, preclin.)	\$343
Immunome	IMNM	IMM-BCP-01	SARS-CoV2 neutralizing mAb combination	discov.	IL-38 for cancer (discov.)	\$182
Checkmate Pharmaceuticals	CMPI	vidutolimod	Virus-like particle encasing CpG-A DNA oligonucleotide for HNSCC immunotherapy	Ph. II	vidutolimod for skin cancer (Ph. 2)	\$111
Aditx Therapeutics Inc	ADTX	ADi-100	CpG-methylated plasmid DNA encoding glutamic acid decarboxylase	preclin.	--	\$35




ALG-010133



GP2 peptide



INZ-701




exoIL-12




FPI-1434



IMM-BCP-01



BA3011



ADi-100